Combo Treatment With Xalnesiran Shows Promise in Patients With Hep B

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 13, 2024 -- For patients with chronic hepatitis B virus (HBV) infection with virologic suppression with nucleoside or nucleotide analog (NA) therapy, xalnesiran plus an immunomodulator results in a substantial percentage of patients with hepatitis B surface antigen (HBsAg) loss, according to a study published in the Dec. 5 issue of the New England Journal of Medicine.

Jinlin Hou, M.D., from Nanfang Hospital in Guangzhou, China, and colleagues conducted a phase 2 multicenter, randomized, controlled trial involving adult patients with chronic HBV infection with virologic suppression with NA therapy to examine 48 weeks of treatment with xalnesiran 100 mg (group 1; 30 patients), xalnesiran 200 mg (group 2; 30 patients), xalnesiran 200 mg + ruzotolimod (group 3; 34 patients), xalnesiran 200 mg + pegylated interferon alfa-2a 180 µg (group 4; 30 patients), or NA alone (group 5; 35 patients). The primary efficacy end point was HBsAg loss at 24 weeks after the end of treatment.

The researchers found that a primary end point event occurred in 7, 3, 12, 23, and 0 percent of patients in groups 1, 2, 3, 4, and 5, respectively. At 24 weeks after the end of treatment, HBsAg seroconversion occurred in 3, 0, 3, 20, and 0 percent of participants, respectively. Only participants with a screening HBsAg level below 1,000 IU/mL had HBsAg loss with or without seroconversion.

"Despite the high percentages of participants with HBsAg loss that were observed in the immunomodulatory-therapy groups at the end of treatment, erosion of this response was observed during the follow-up period," the authors write.

The study was funded by F. Hoffmann-La Roche, which is developing xalnesiran.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-14 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords